| 000 | 01804 a2200493 4500 | ||
|---|---|---|---|
| 005 | 20250515140849.0 | ||
| 264 | 0 | _c20090107 | |
| 008 | 200901s 0 0 spa d | ||
| 022 | _a0213-005X | ||
| 024 | 7 |
_a10.1157/13125637 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aPalacios, Ricardo | |
| 245 | 0 | 0 |
_a[Factors associated with virological response in women receiving highly-active antiretroviral prophylaxis for HIV-1 mother-to-child transmission]. _h[electronic resource] |
| 260 |
_bEnfermedades infecciosas y microbiologia clinica _c |
||
| 300 |
_a411-5 p. _bdigital |
||
| 500 | _aPublication Type: English Abstract; Journal Article | ||
| 650 | 0 | 4 | _aAdolescent |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aAnti-HIV Agents _xadverse effects |
| 650 | 0 | 4 |
_aAntiretroviral Therapy, Highly Active _xadverse effects |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aFollow-Up Studies |
| 650 | 0 | 4 | _aGestational Age |
| 650 | 0 | 4 |
_aHIV Infections _xblood |
| 650 | 0 | 4 |
_aHIV Protease Inhibitors _xadverse effects |
| 650 | 0 | 4 | _aHIV-1 |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aInfant, Newborn |
| 650 | 0 | 4 |
_aInfectious Disease Transmission, Vertical _xprevention & control |
| 650 | 0 | 4 | _aLopinavir |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aPregnancy |
| 650 | 0 | 4 |
_aPregnancy Complications, Infectious _xblood |
| 650 | 0 | 4 |
_aPyrimidinones _xadverse effects |
| 650 | 0 | 4 |
_aReverse Transcriptase Inhibitors _xadverse effects |
| 650 | 0 | 4 | _aRisk |
| 650 | 0 | 4 |
_aViral Load _xstatistics & numerical data |
| 650 | 0 | 4 |
_aViremia _xdrug therapy |
| 700 | 1 | _aSenise, Jorge F | |
| 700 | 1 | _aVaz, Maria Josév R | |
| 700 | 1 | _aCastelo, Adauto | |
| 773 | 0 |
_tEnfermedades infecciosas y microbiologia clinica _gvol. 26 _gno. 7 _gp. 411-5 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1157/13125637 _zAvailable from publisher's website |
| 999 |
_c18308089 _d18308089 |
||